FDA Investigator Yiwei Li
Yiwei Li has conducted inspections on 4 sites in 2 countries as of 14 Feb 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
4
Last Inspection Date:
14 Feb 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America,
China
FDA Investigators that have inspected at least one site in common with Yiwei Li:
Ava M Bowman,
Benjamin J Smith,
Brentley S Collins,
Burnell M Henry,
Charles M Spyr,
Cheng H Yen,
Constantin Y Philopoulos,
David A Paterson,
Dr. Jun Liu, PhD,
Emest F Bizjak,
Emily J Orban,
Emine Guvenmaiorov,
Enrico Joset Mangahis,
Gene D Arcy,
Helen B Ricalde,
Ifueko Osemwota,
Jeffrey A Sommers,
Jeffrey D Meng,
Jennifer L Schmidt,
Kham Phommachanh,
Larry K Austin,
Laurimer Kuilan Torres,
Lindsey Brown, PhD,
Meisha R Sampson,
Meisha Waters,
Michele L Forster, PhD,
Michele L Glendenning,
Patsy J Domingo,
Paula A Trost,
Peng Zhou,
Ralph A Erickson,
Rebecca E Dombrowski,
Rebecca K Olin,
Richard Ledwidge (nmi), PhD,
Robert M Barbosa,
Rose Ashley,
Rose Xu,
Sarah B Tanksley,
Sarah M Meng,
Sarah M Napier,
Scott T Ballard,
Simone E Pitts,
Susan M Jackson,
Tonia F Bernard,
Wayne E Seifert,
Zhong Li, PhD
Yiwei Li's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| February, 2024 | FDA 483 | Baxter Pharmaceutical Solutions LLC - Form 483, 2024-02-20 |
| November, 2023 | FDA 483 | FUJIFILM Diosynth Biotechnologies Texas, LLC - Form 483, 2023-11-07 |
| December, 2023 | FDA 483 | Suzhou Suncadia Biopharmaceuticals Co., Ltd - Form 483, 2023-12-14 |
| June, 2023 | EIR | Boehringer Ingelheim Biopharmaceuticals (China) Ltd. - EIR, 2023-12-28 |
| June, 2024 | FDA 483 | STgen Bio Co., Ltd. - Form 483, 2024-06-25 |
| December, 2023 | EIR | Suzhou Suncadia Biopharmaceuticals Co., Ltd - EIR, 2024-07-16 |
| July, 2024 | FDA 483 | Samsung Biologics Co., Ltd. - Form 483, 2024-07-30 |
| June, 2023 | FDA 483 | Boehringer Ingelheim Biopharmaceuticals (China) Ltd. - Form 483, 2023-06-09 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more